Search Results - "Dai, Charles S"

Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis by Gerratana, Lorenzo, Davis, Andrew A, Velimirovic, Marko, Clifton, Katherine, Hensing, Whitney L, Shah, Ami N, Dai, Charles S, Reduzzi, Carolina, D'Amico, Paolo, Wehbe, Firas, Medford, Arielle, Wander, Seth A, Gradishar, William J, Behdad, Amir, Puglisi, Fabio, Ma, Cynthia X, Bardia, Aditya, Cristofanilli, Massimo

“…although being central for the biology and druggability of hormone-receptor positive, HER2 negative metastatic breast cancer (MBC), ESR1 and PIK3CA mutations…”
Get full text

Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child by Keenan, Jennifer C, Medford, Arielle J, Dai, Charles S, Wander, Seth A, Spring, Laura M, Bardia, Aditya

“…Estrogen receptor positive (ER+) breast cancer is the most common breast cancer subtype, and therapeutic management relies primarily on inhibiting ER…”
Get full text

Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer by Hensing, Whitney L, Gerratana, Lorenzo, Clifton, Katherine, Medford, Arielle J, Velimirovic, Marko, Shah, Ami N, D'Amico, Paolo, Reduzzi, Carolina, Zhang, Qiang, Dai, Charles S, Denault, Elyssa N, Bagegni, Nusayba A, Opyrchal, Mateusz, Ademuyiwa, Foluso O, Bose, Ron, Behdad, Amir, Ma, Cynthia X, Bardia, Aditya, Cristofanilli, Massimo, Davis, Andrew A

“…About 50% of breast cancers are defined as HER2-low and may benefit from HER2-directed antibody-drug conjugates. While tissue sequencing has evaluated…”
Get full text

TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis by Medford, Arielle J., Oshry, Lauren, Boyraz, Baris, Kiedrowski, Lesli, Menshikova, Sofia, Butusova, Anna, Dai, Charles S., Gogakos, Tasos, Keenan, Jennifer C., Occhiogrosso, Rachel H., Ryan, Phoebe, Lennerz, Jochen K., Spring, Laura M., Moy, Beverly, Ellisen, Leif W., Bardia, Aditya

“…Tissue-agnostic indications for targeted therapies have expanded options for patients with advanced solid tumors. The Food and Drug Administration approvals of…”
Get full text

Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer by Davis, Andrew A., Gerratana, Lorenzo, Clifton, Katherine, Medford, Arielle J., Velimirovic, Marko, Hensing, Whitney L., Bucheit, Leslie, Shah, Ami N., D'Amico, Paolo, Reduzzi, Carolina, Zhang, Qiang, Dai, Charles S., Denault, Elyssa N., Bagegni, Nusayba A., Opyrchal, Mateusz, Ademuyiwa, Foluso O., Bose, Ron, Gradishar, William J., Behdad, Amir, Ma, Cynthia X., Bardia, Aditya, Cristofanilli, Massimo

“…Limited data exist to characterise molecular differences in circulating tumour DNA (ctDNA) for patients with invasive lobular carcinoma (ILC). We analysed…”
Get full text

Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis by Gerratana, Lorenzo, Davis, Andrew A, Velimirovic, Marko, Reduzzi, Carolina, Clifton, Katherine, Bucheit, Leslie, Hensing, Whitney L, Shah, Ami N, Pivetta, Tania, Dai, Charles S, D'Amico, Paolo, Wehbe, Firas, Medford, Arielle, Wander, Seth A, Gradishar, William J, Behdad, Amir, Ma, Cynthia X, Puglisi, Fabio, Bardia, Aditya, Cristofanilli, Massimo

“…As the continuation beyond progression (BP) of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) is becoming increasingly attractive for the treatment of…”
Get more information

Abstract P2-07-02: Genomic predictors of rapid progression to first line endocrine and CDK4/6 inhibitor combination therapy in patients with estrogen receptor positive (ER+) HER-2 negative (HER2-) advanced breast cancer (ABC) by Velimirovic, Marko, Gerratana, Lorenzo, Davis, Andrew A, Hensing, Whitney L, Clifton, Katherine, Shah, Ami N, D'Amico, Paolo, Dai, Charles S, Denault, Elyssa N, Ma, Cynthia X, Wander, Seth A, Juric, Dejan, Cristofanilli, Massimo, Chabner, Bruce A, Bardia, Aditya

“…Abstract Background: Endocrine therapy with CDK 4/6 inhibitors (ET/CDK4/6i) represents the 1st line therapy for ER+/HER2- ABC. While majority of patients…”
Get full text

Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer analysis by Gerratana, Lorenzo, Davis, Andrew A, Velimirovic, Marko, Clifton, Katherine, Hensing, Whitney L, Shah, Ami N, Dai, Charles S, Reduzzi, Carolina, D'Amico, Paolo, Wehbe, Firas, Medford, Arielle, Wander, Seth A, Gradishar, William J, Behdad, Amir, Puglisi, Fabio, Ma, Cynthia X, Bardia, Aditya, Cristofanilli, Massimo

“…Background although being central for the biology and druggability of hormone-receptor positive, HER2 negative metastatic breast cancer (MBC), ESR1 and PIK3CA…”
Get full text

Abstract P2-01-01: Genetic alterations detected by circulating tumor DNA (ctDNA) in HER2-low metastatic breast cancer (MBC) by Hensing, Whitney L, Gerratana, Lorenzo, Clifton, Katherine, Velimirovic, Marko, Shah, Ami, D'Amico, Paolo, Reduzzi, Carolina, Zhang, Qiang, Dai, Charles S, Bagegni, Nusayba A, Opyrchal, Mateusz, Ademuyiwa, Foluso O, Ron, Bose, Behdad, Amir, Ma, Cynthia X, Bardia, Aditya, Cristofanilli, Massimo, Davis, Andrew A

“…Abstract Introduction: Approximately 40-50% of breast cancers are characterized by low HER2 expression (HER2-low), defined as immunohistochemistry (IHC) 1+ or…”
Get full text

Abstract PD6-08: Exploring the interplay among ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype of metastatic breast cancer (MBC) through circulating tumor DNA (ctDNA) next-generation sequencing (NGS) by Gerratana, Lorenzo, Davis, Andrew A, Velimirovic, Marko, Clifton, Katherine, Hensing, Whitney L, Shah, Ami N, Dai, Charles S, Reduzzi, Carolina, D’Amico, Paolo, Zhang, Qiang, Wehbe, Firas, Wander, Seth, Gradishar, William J, Behdad, Amir, Puglisi, Fabio, Ma, Cynthia X, Bardia, Aditya, Cristofanilli, Massimo

“…Abstract Background: High throughput genomic technologies such as NGS are enhancing the ability to dynamically characterize MBC but their role in describing…”
Get full text

Abstract PD14-04: Circulating tumor DNA characterization of invasive lobular carcinoma in patients with metastatic breast cancer by Davis, Andrew A, Gerratana, Lorenzo, Clifton, Katherine, Velimirovic, Marko, Hensing, Whitney L, Shah, Ami N, D’Amico, Paolo, Reduzzi, Carolina, Zhang, Qiang, Dai, Charles S, Denault, Elyssa N, Bagegni, Nusayba A, Opyrchal, Mateusz, Ademuyiwa, Foluso O, Bose, Ron, Gradishar, William J, Behdad, Amir, Ma, Cynthia X, Bardia, Aditya, Cristofanilli, Massimo

“…Abstract Background:Invasive lobular carcinoma (ILC) is the second most common histology of breast cancer, accounting for approximately 10-15% of cases. Prior…”
Get full text

Abstract P5-02-13: TRK inhibitor in a patient with metastatic triple negative breast cancer and NTRK fusions identified via cell-free DNA analysis by Keenan, Jennifer C., Medford, Arielle J., Oshry, Lauren J., Boyraz, Baris, Dai, Charles S., Kiedrowski, Lesli A., Menshikova, Sofia, Butusova, Anna, Gogakos, Tasos, Occhiogrosso, Rachel, Ryan, Phoebe, Lennerz, Jochen, Spring, Laura M., Moy, Beverly, Ellisen, Leif, Bardia, Aditya

“…Abstract Introduction: Tissue-agnostic indications for targeted therapies are expanding options for patients with advanced solid tumors. The FDA approvals of…”
Get full text

Abstract PO4-15-04: Differential genomic profiling of progesterone receptor (PR) negative, estrogen receptor (ER) positive HER2-negative metastatic breast cancer (MBC) through circulating tumor DNA by Gerratana, Lorenzo, Davis, Andrew, Medford, Arielle, Reduzzi, Carolina, Clifton, Katherine, Podany, Emily, Hensing, Whitney, Velimirovic, Marko, Shah, Ami N., Foffano, Lorenzo, Arcos, Laura Munoz, Nicolò, Eleonora, Dai, Charles S., Keenan, Jennifer, Behdad, Amir, Wander, Seth, Gradishar, William, Ma, Cynthia, Puglisi, Fabio, Bardia, Aditya, Cristofanilli, Massimo

“…Abstract Background: MBC is usually classified based on ER and HER2 status. Although the absence of PR expression is commonly associated with a poorer response…”
Get full text

Abstract PO5-15-02: Integration of synonymous mutations and variants of unknown significance for basal and longitudinal characterization of metastatic breast cancer by circulating tumor DNA by Molteni, Elisabetta, Reduzzi, Carolina, Davis, Andrew, Foffano, Lorenzo, Medford, Arielle, Clifton, Katherine, Hensing, Whitney L., Velimirovic, Marko, Shah, Ami N., Arcos, Laura Munoz, Dai, Charles S., Keenan, Jennifer C., Denault, Elyssa, Gradishar, William, Damante, Giuseppe, Behdad, Amir, Gerratana, Lorenzo, Puglisi, Fabio, Ma, Cynthia, Bardia, Aditya, Cristofanilli, Massimo

“…Abstract Background: Despite how commonly synonymous mutations (SYN) and unknown significance (VUS) are detected in tissue and circulating tumor DNA (ctDNA)…”
Get full text

Abstract PO4-15-06: Genomic landscape characterization after exposure to cyclin dependent kinase 4/6 inhibitors: a retrospective multi-institutional consortium analysis by Pontolillo, Letizia, Reduzzi, Carolina, Davis, Andrew, Gerratana, Lorenzo, Medford, Arielle, Clifton, Katherine, Hensing, Whitney L., Velimirovic, Marko, Shah, Ami N., Donahue, Jeannine, Arcos, Laura Munoz, Dai, Charles S., Keenan, Jennifer, Behdad, Amir, Gradishar, William, Bria, Emilio, Ma, Cynthia, Bardia, Aditya, Cristofanilli, Massimo

“…Abstract Background: Limited data are available to determine the best therapeutic strategy for hormone-receptor positive (HR+) HER2 negative (HER2-) advanced…”
Get full text

Abstract PS06-03: Differences in ctDNA genomic profiles and outcomes of Black and White patients with metastatic breast cancer: results from a large multicenter consortium by Podany, Emily, Foffano, Lorenzo, Gerratana, Lorenzo, Medford, Arielle, Clifton, Katherine, Hensing, Whitney, Morecroft, Renee, Velimirovic, Marko, Shah, Ami, REDUZZI, Carolina, Arcos, Laura Munoz, Dai, Charles S., Keenan, Jennifer, Denault, Elyssa, Ademuyiwa, Foluso, Puglisi, Fabio, Ma, Cynthia, Bardia, Aditya, Cristofanilli, Massimo, Davis, Andrew

“…Abstract Background: Black breast cancer patients have a well-documented survival disparity when compared to White patients. It is imperative to explore the…”
Get full text

Abstract 977: Germline BRCA1/2 mutations detected by circulating tumor DNA testing in breast cancer patients: A retrospective mutiinstitutional analysis by Pontolillo, Letizia, Reduzzi, Carolina, Davis, Andrew A., Medford, Arielle J., Putur, Annika, Gerratana, Lorenzo, Clifton, Katherine, Hensing, Whitney L., Velimirovic, Marko, Warrior, Surbhi, Serafini, Mara S., Nicolò, Eleonora, Munoz-Arcos, Laura, Donahue, Jeannine, Dai, Charles S., Keenan, Jennifer C., Behdad, Amir, Gradishar, William J., Giannarelli, Diana, Bria, Emilio, Ma, Cynthia X., Bardia, Aditya, Cristofanilli, Massimo

“…Abstract Background: The use of circulating tumor (ct) DNA testing allows to detect resistant and actionable somatic alterations and it could be associated…”
Get full text

TRK inhibitor in a patient with metastatic triple-negative breast cancer and fusions identified cell-free DNA analysis by Arielle J. Medford, Lauren Oshry, Baris Boyraz, Lesli Kiedrowski, Sofia Menshikova, Anna Butusova, Charles S. Dai, Tasos Gogakos, Jennifer C. Keenan, Rachel H. Occhiogrosso, Phoebe Ryan, Jochen K. Lennerz, Laura M. Spring, Beverly Moy, Leif W. Ellisen, Aditya Bardia

“…Tissue-agnostic indications for targeted therapies have expanded options for patients with advanced solid tumors. The Food and Drug Administration approvals of…”
Get full text

Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancerResearch in context by Andrew A. Davis, Lorenzo Gerratana, Katherine Clifton, Arielle J. Medford, Marko Velimirovic, Whitney L. Hensing, Leslie Bucheit, Ami N. Shah, Paolo D'Amico, Carolina Reduzzi, Qiang Zhang, Charles S. Dai, Elyssa N. Denault, Nusayba A. Bagegni, Mateusz Opyrchal, Foluso O. Ademuyiwa, Ron Bose, William J. Gradishar, Amir Behdad, Cynthia X. Ma, Aditya Bardia, Massimo Cristofanilli

“…Background: Limited data exist to characterise molecular differences in circulating tumour DNA (ctDNA) for patients with invasive lobular carcinoma (ILC). We…”
Get full text

Abstract P5-02-07: Cell-free DNA detection of GATA3 mutations in metastatic hormone receptor positive breast cancer: a retrospective, observational multi-institutional analysis by Medford, Arielle J., Velimirovic, Marko, Niemierko, Andrzej, Hensing, Whitney L., Davis, Andrew A., Clifton, Katherine K., Keenan, Jennifer C., Dai, Charles S., Kiedrowski, Lesli A., Shah, Ami N., Gerratana, Lorenzo, Spring, Laura M., Ellisen, Leif, Doebele, Robert C., Cristofanilli, Massimo, Bardia, Aditya

“…Abstract Background GATA3 mutations (GATA3mut) have been reported in 10-20% of hormone receptor positive (HR+) breast cancers. It has been shown that targeting…”
Get full text